Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?
A positive outcome in the SHARP study is good news for Merck, but questions still remain about the efficacy of Vytorin compared to older statins.
A positive outcome in the SHARP study is good news for Merck, but questions still remain about the efficacy of Vytorin compared to older statins.